Novavax COVID-19 Vaccine Highly Effective in Pivotal Phase 3 Trial – Pulmonology Advisor

Novavax’s COVID-19 vaccine candidate achieved an overall vaccine efficacy of 90.4% and 100% efficacy against moderate and severe COVID-19.

Read the full article here

Related Articles